Clinical Trials · NCT05611957
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 29
- Start date
- Nov 2022
- Locations
- 4 sites, United States
- Primary endpoint
- Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943